FDA Expands REMS Training to Include More Opioids, More Health Care Providers
In September, the FDA approved a new Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) that expands upon the previous (2012) ER/LA Opioid REMS. The new REMS requires training also be made available on immediate-release opioid analgesics and offered to prescribers and nonprescribers alike who are involved in the [...]